TerminatedPhase 1

Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD

Stopped: The study was terminated prematurely due to the lack of availability of the study drug.

Puerto Rico36 participantsStarted 2022-01-21

Plain-language summary

To determine the efficacy of deutetrabenazine to control symptoms of dysphagia associated with HD.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Confirmed diagnosis of HD * Symptoms of dysphagia * Must be able to swallow tablets Exclusion Criteria: * Other confounding diseases that affect swallowing * Depression * Hepatic impairment * Renal impairment * Dementia

What they're measuring

Efficacy of deutetrabenazine to control symptoms of dysphagia associated with Huntington's disease.

Timeframe: 18 months

Non-instrumental assessment of the efficacy of deutetrabenazine to control symptoms of dysphagia associated with Huntington's disease.

Timeframe: 18 months

Instrumental assessment of the efficacy of deutetrabenazine to control symptoms of dysphagia associated with Huntington's disease.

Timeframe: 18 months

Trial details

NCT IDNCT04301726

SponsorFundacion Huntington Puerto Rico

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-08-18

View on ClinicalTrials.gov More Huntington Disease trials